237 related articles for article (PubMed ID: 30561730)
21. Infectious complications in geriatric renal transplant patients: comparison of two immunosuppressive protocols.
Meier-Kriesche HU; Friedman G; Jacobs M; Mulgaonkar S; Vaghela M; Kaplan B
Transplantation; 1999 Nov; 68(10):1496-502. PubMed ID: 10589946
[TBL] [Abstract][Full Text] [Related]
22. The influence of HLA mismatches and immunosuppression on kidney graft survival: an analysis of more than 1300 patients.
Martins L; Fonseca I; Sousa S; Matos C; Santos J; Dias L; Henriques AC; Sarmento AM; Cabrita A
Transplant Proc; 2007 Oct; 39(8):2489-93. PubMed ID: 17954156
[TBL] [Abstract][Full Text] [Related]
23. 15-year follow-up of a multicenter, randomized, calcineurin inhibitor withdrawal study in kidney transplantation.
Roodnat JI; Hilbrands LB; Hené RJ; de Sévaux RG; Smak Gregoor PJ; Kal-van Gestel JA; Konijn C; van Zuilen A; van Gelder T; Hoitsma AJ; Weimar W
Transplantation; 2014 Jul; 98(1):47-53. PubMed ID: 24521775
[TBL] [Abstract][Full Text] [Related]
24. Tac-MMF Versus CsA-MMF/CsA-AZA-Based Regimens in Development of De Novo Complement-Binding Anti-HLA Antibodies After Kidney Transplantation.
Sahutoglu T; Akgul SU; Caliskan Y; Yazici H; Demir E; Kara E; Temurhan S; Savran FO; Turkmen A
Transplant Proc; 2017 Apr; 49(3):454-459. PubMed ID: 28340811
[TBL] [Abstract][Full Text] [Related]
25. Donor-Specific Anti-Human Leukocyte Antigens Antibodies, Acute Rejection, Renal Function, and Histology in Kidney Transplant Recipients Receiving Tacrolimus and Everolimus.
Ferreira A; Felipe C; Cristelli M; Viana L; Basso G; Stopa S; Mansur J; Ivani M; Bessa A; Ruppel P; Aguiar W; Campos E; Gerbase-DeLima M; Proença H; Tedesco-Silva H; Medina-Pestana J
Am J Nephrol; 2017; 45(6):497-508. PubMed ID: 28511172
[TBL] [Abstract][Full Text] [Related]
26. Randomized trial of 3 maintenance regimens (TAC/SRL vs. TAC/MMF vs. CSA/SRL) with low-dose corticosteroids in primary kidney transplantation: 18-year results.
Ciancio G; Gaynor JJ; Guerra G; Roth D; Chen L; Kupin W; Mattiazzi A; Ortigosa-Goggins M; Moni L; Burke GW
Clin Transplant; 2020 Dec; 34(12):e14123. PubMed ID: 33070366
[TBL] [Abstract][Full Text] [Related]
27. Effects of mycophenolate mofetil on donor-specific antibody formation in renal transplantation.
Lederer SR; Friedrich N; Banas B; Welser G; Albert ED; Sitter T
Clin Transplant; 2005 Apr; 19(2):168-74. PubMed ID: 15740551
[TBL] [Abstract][Full Text] [Related]
28. Sirolimus vs mycophenolate moftile in Tacrolimus based therapy following induction with Antithymocyte globulin promotes regulatory T cell expansion and inhibits RORγt and T-bet expression in kidney transplantation.
Jamali S; Sarafnejad A; Ahmadpoor P; Nafar M; Karimi M; Eteghadi A; Yekaninejad MS; Amirzargar AA
Hum Immunol; 2019 Sep; 80(9):739-747. PubMed ID: 30597187
[TBL] [Abstract][Full Text] [Related]
29. Clinical and cost-effectiveness of newer immunosuppressive regimens in renal transplantation: a systematic review and modelling study.
Woodroffe R; Yao GL; Meads C; Bayliss S; Ready A; Raftery J; Taylor RS
Health Technol Assess; 2005 May; 9(21):1-179, iii-iv. PubMed ID: 15899149
[TBL] [Abstract][Full Text] [Related]
30. Effect of immunosuppressive regimen on acute rejection and liver graft function.
Ziolkowski J; Paczek L; Niewczas M; Senatorski G; Oldakowska-Jedynak U; Wyzgal J; Foroncewicz B; Mucha K; Zegarska J; Nyckowski P; Zieniewicz K; Patkowski W; Krawczyk M; Ziarkiewicz-Wroblewska B; Gornicka B
Transplant Proc; 2003 Sep; 35(6):2281-3. PubMed ID: 14529915
[TBL] [Abstract][Full Text] [Related]
31. Conversion from tacrolimus-mycophenolate mofetil to tacrolimus-mTOR immunosuppression after kidney-pancreas transplantation reduces the incidence of both BK and CMV viremia.
Knight RJ; Graviss EA; Nguyen DT; Kuten SA; Patel SJ; Gaber L; Gaber AO
Clin Transplant; 2018 Jun; 32(6):e13265. PubMed ID: 29676018
[TBL] [Abstract][Full Text] [Related]
32. [Effectiveness and safety of conversion therapy with the combination of sirolimus with low dose cyclosporine in renal transplantation recipients: a five-year clinical observation].
Zhu L; Ding T; Wang XX; Lin ZB; Chen G
Zhonghua Yi Xue Za Zhi; 2016 May; 96(20):1556-61. PubMed ID: 27266681
[TBL] [Abstract][Full Text] [Related]
33. Long-term renal transplant function in recipient of simultaneous kidney and pancreas transplant maintained with two prednisone-free maintenance immunosuppressive combinations: tacrolimus/mycophenolate mofetil versus tacrolimus/sirolimus.
Gallon LG; Winoto J; Chhabra D; Parker MA; Leventhal JR; Kaufman DB
Transplantation; 2007 May; 83(10):1324-9. PubMed ID: 17519781
[TBL] [Abstract][Full Text] [Related]
34. Long-term follow-up of a phase III clinical trial comparing tacrolimus extended-release/MMF, tacrolimus/MMF, and cyclosporine/MMF in de novo kidney transplant recipients.
Silva HT; Yang HC; Meier-Kriesche HU; Croy R; Holman J; Fitzsimmons WE; First MR
Transplantation; 2014 Mar; 97(6):636-41. PubMed ID: 24521771
[TBL] [Abstract][Full Text] [Related]
35. Minimization of maintenance immunosuppressive therapy after renal transplantation comparing cyclosporine A/azathioprine or cyclosporine A/mycophenolate mofetil bitherapy to cyclosporine A monotherapy: a 10-year postrandomization follow-up study.
Thierry A; Le Meur Y; Ecotière L; Abou-Ayache R; Etienne I; Laurent C; Vuiblet V; Colosio C; Bouvier N; Aldigier JC; Rerolle JP; Javaugue V; Gand E; Bridoux F; Essig M; Hurault de Ligny B; Touchard G
Transpl Int; 2016 Jan; 29(1):23-33. PubMed ID: 26729582
[TBL] [Abstract][Full Text] [Related]
36. Ten-year observational follow-up of a randomized trial comparing cyclosporine and tacrolimus therapy combined with steroid withdrawal in living-donor renal transplantation.
Kim J; Park J; Hwang S; Yoo H; Kim K; Park JB; Jang HR; Lee JE; Kim SJ; Kim YG; Kim DJ; Oh HY; Huh W
Clin Transplant; 2018 Sep; 32(9):e13372. PubMed ID: 30080284
[TBL] [Abstract][Full Text] [Related]
37. Long-term outcomes after cyclosporine or mycophenolate withdrawal in kidney transplantation - results from an aborted trial.
Åsberg A; Apeland T; Reisaeter AV; Foss A; Leivestad T; Heldal K; Thorud LO; Eriksen BO; Hartmann A;
Clin Transplant; 2013; 27(2):E151-6. PubMed ID: 23351013
[TBL] [Abstract][Full Text] [Related]
38. Mycophenolate mofetil, an alternative to cyclosporine A for long-term immunosuppression in kidney transplantation?
Houde I; Isenring P; Boucher D; Noël R; Lachanche JG
Transplantation; 2000 Oct; 70(8):1251-3. PubMed ID: 11063351
[TBL] [Abstract][Full Text] [Related]
39. Tacrolimus plus mycophenolate mofetil vs. cyclosporine plus everolimus in deceased donor kidney transplant recipients: three-yr results of a single-center prospective clinical trial.
Favi E; Spagnoletti G; Salerno MP; Pedroso JA; Romagnoli J; Citterio F
Clin Transplant; 2013; 27(4):E359-67. PubMed ID: 23710603
[TBL] [Abstract][Full Text] [Related]
40. BK viremia surveillance after kidney transplant: single-center experience during a change from cyclosporine-to lower-dose tacrolimus-based primary immunosuppression regimen.
Geddes CC; Gunson R; Mazonakis E; Wan R; Thomson L; Clancy M; Carman WF
Transpl Infect Dis; 2011 Apr; 13(2):109-16. PubMed ID: 21457419
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
